Novel system to treat hair loss receives CE Mark approval

Restoration Robotics, Inc., a privately-held medical device company, today announced its revolutionary ARTAS® System received CE Mark Certificate (Conformité Européenne) to market in the European Union. The ARTAS System is the first physician controlled, computer assisted technology that allows harvesting individual follicular units directly from the scalp. This minimally invasive solution utilizes sophisticated digital mapping and precision robotics to deliver permanent and natural looking results.

“We have seen strong interest in bringing the ARTAS System to Europe, and we can now move forward with our expansion plans.”

"Receiving the CE Mark for Europe is a major milestone that indicates our FDA-cleared solution also meets the quality and safety standards required by the international healthcare marketplace," said Jim McCollum, President and Chief Executive Officer, Restoration Robotics, Inc. "We have seen strong interest in bringing the ARTAS System to Europe, and we can now move forward with our expansion plans."

Hair Loss By The Numbers

Hair loss affects approximately 50% of all men and over 25% of all women worldwide. Over 35 million men are affected by male pattern baldness (androgenetic alopecia) in the United States alone. Approximately two-thirds of American men will experience appreciable hair loss by age 35; by age 50, 85% will see significant loss in hair thickness. Genetic hair loss, which typically begins between late adolescence and before or during middle age, is largely untreatable outside of surgery.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breathing New Life into Diagnostics: Plasmion's SICRIT® Technology